Join to View Full Profile
170 University of NCTrlr CbChapel Hill, NC 27599
Phone+1 732-236-3903
Dr. Zeidner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014- Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
New York Medical CollegeClass of 2008
Certifications & Licensure
NC State Medical License 2014 - 2025
MD State Medical License 2011 - 2015
American Board of Internal Medicine Medical Oncology
Clinical Trials
- High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Start of enrollment: 2016 Aug 22
- A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS Start of enrollment: 2018 Aug 29
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Start of enrollment: 2022 Aug 24
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.Daniel T Peters, Joshua F Zeidner
Cancer. 2025-04-15 - Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Blood Cancer Journal. 2025-04-03 - Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.Hetty E Carraway, Andrew M Brunner, Catherine E Lai, Marlise R Luskin, Jae Park
Clinical Lymphoma, Myeloma & Leukemia. 2025-03-13
Journal Articles
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
Abstracts/Posters
- OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid LeukemiaJoshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)Joshua Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid TumorsJoshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Press Mentions
Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual MeetingDecember 9th, 2024- Syndax Announces Additional Positive Data for Revuforj® (Revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialDecember 9th, 2024
- QTc Formula Affects Heart Rhythm Assessment, Chemotherapy DoseSeptember 30th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
